Ficlatuzumab - CAS 1174900-84-5

Ficlatuzumab is a humanized monoclonal antibody that specifically targets and neutralizes the biological activity of human hepatocyte growth factor (HGF), by inhibiting HGF, Ficlatuzumab effectively blocks c-Met receptor-mediated downstream signaling pathways responsible for cancer cell proliferation, migration, and invasion, demonstrating applicable use for the treatment of squamous cell carcinoma.

C-Met/HGFR

Tyrosine Kinase/Adaptors

1174811

0.99

-20°C

Ice Packs

Inhibitory Antibodies